Oncology

The Monash Health Department of Oncology provides more than 1.5 million residents of southern Melbourne with access to world leading cancer treatment over four locations within the Monash Health service:

Moorabbin Hospital: Breast cancer, GI cancer, GU cancer, Lung cancer, Head & Neck cancer, Gynecological cancer, Urologic cancer

Dandenong Hospital: General Oncology, Geriatric Oncology

Casey Hospital: General Oncology

Monash Health Translation Precinct (MHTP building Level 3). Monash Medical Centre, Clayton: Cancer Clinical Trials

Monash Medical Centre Clayton: Neuro-oncology (Brain Cancer)

Our Services

Cancer patients receive care from diagnosis to treatment and follow-up support. Through collaborative multidisciplinary team framework we provide the Medical Oncology aspect of cancer care, integrating with teams from surgical and radiation oncology and Palliative and Supportive care.

Our Staff

Department Head

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP
Professor/Director of Oncology
Gastrointestinal Cancers Neuroendocrine Tumours 

Senior Leadership Team

A/Prof. Arun Azad MBBS FRACP PhD
Head of Oncology Trials
Genitourinary Cancer

A/Prof. Michael Franco MBBS FRACP FAChPM
Head of Oncology Operations and Education
Palliative Medicine, Breast and Gastrointestinal Cancer

A/Prof. Jake Shortt BMedSc MBChB FRACP FRCPA PhD
Head of Translational Research, Haematologist

Dr. Michelle White MBBS GDipPallMed FRACP
Head of Oncology Quality and Safety, Breast Cancer

Senior Medical Staff

Dr. Muhammad Alamgeer MBBS MD MRCP FRACP
Head and Neck Cancer

Dr. Peter Briggs MBBS FRACP
Lung Cancer

Dr. Puey Ling Chia MBBS MRCP FRACP
Medical Oncologist (Locum Casey Hospital)

Dr. Daphne Day MBBS (Hons), FRACP
Breast, Head and Neck Cancer and Phase 1 trials

Dr. Sophia Frentzas MBBS BSc (Hons) MRCP (UK) PHD MRCP (Med Onc UK) PGDip (Oncology) FRACP
Gastrointestinal, Breast and Gynaecological Cancer

Dr. Geraldine Goss MBBS FRACP MD MMED
Gynaecological Cancer

A/Prof. Marion Harris MBBS FRACP
Director of Familial Cancer, Gastrointestinal and Breast Cancer

Dr. Edmond Kwan MBBS FRACP
Genitourinary Cancer

Dr. Esther Lin MBBS FRACP FAChPM FRACP
Palliative Medicine

Dr. Ben Markman MBBS FRACP
Phase 1 Trials, Lung, Gastrointestinal Cancer

Dr. Sagun Parakh BSc MbChB FRACP
Phase 1 Trials, Lung Cancer and Neuro-Oncology (Brain Cancer)

Dr. David Pook BMedSci (Hons) MBBS FRACP MD
Genitourinary Cancer

Dr. Ranjana Srivastava MBBS FRACP
Breast, Gastrointestinal Cancer, Geriatric Oncology

A/Prof. Andrew Strickland MBBS FRACP
Gastrointestinal Cancer

Clinical Trials Fellows

Dr. Siddharth Menon MBBS

Dr. Chun Gan MBBS

Advanced Trainees 

Dr. Adithya Balasubramanian

Dr. Caroline Lum

Dr. Gabrielle Lie

Dr. Katie Tham

Clinical Trials Research Staff

Ms. Karen Gillett
Oncology Research Manager

Ms. Merylyn Ryan
Oncology Research Operations Manager

Study Coordinators

Ms. Cheryl-Ann Hawkins
Study Coordinator

Ms. Penny McGuire
Study Coordinator

Ms. Chris Brooks
Study Coordinator

Ms. Louise Davis
Study Coordinator

Ms. Chris Poole
Study Coordinator

Ms. Laima Muceneikas
Study Coordinator

Ms. Lindsay Thompson
Study Coordinator

Ms. Shelley Firth
Study Coordinator

Ms. Lisa Robinson
Study Coordinator

Ms. Kim Brewin
Study Coordinator

Ms. Frances Bishop
Study Coordinator

Ms. Linda Garrett
Study Coordinator

Ms. Isabelle Nehma
Study Coordinator

Ms. Stephanie Kaladis
Study Coordinator

Ms. Lauren Curtain
Study Coordinator

Ms. Joanna Maggs
Ethics Submission Specialist

Ms. Sabah Saad
Ethics Submission Specialist

Clinical Trials Assistants

Ms. Julie Kavanagh
Clinical Trial Assistant

Mr. Simon O'Neill
Clinical Trial Assistant

Ms. Kristy Horvath
Clinical Trial Assistant

Ms. Deborah Chang
Clinical Trial Assistant

Ms. Michelle Zheng
Clinical Trial Assistant

Laboratory Assistants

Ms. Dixita Desai
Laboratory Assistant

Ms. Susan Alford
Laboratory Assistant

Nurse Practitioners

Ms. Vicki McLeod - Nurse Practitioner

Ms. Gillian Kruss - Metastatic Breast Cancer

Ms. Katie Evans - McGrath Foundation Breast Cancer Nurse

Support and Administration Staff

Ms. Annette McClellan
Oncology Department Secretary/PA to Professor Segelov.
E: Annette.McClellan@monashhealth.org
P: +61 3 8572 2392

Ms. Sarah Niazmand
Oncology Research Administration Assistant
E: Sarah.Niazmand@monashhealth.org
P: +61 3 8572 2390 or +61 3 8572 22021

Translational Research Staff

Gastrointestinal Cancer Research Group

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP
Group Leader

Dr. Maja Green PhD, MSc,BSc (Hons)
Post Doctoral Fellow

Dr. Daphne Day MBBS (Hons), FRACP
PhD Student

Dr. Sameer Greenall PhD, BSc (Hons)
Research Fellow

Mr. Cameron Naidu MBBS
Honours Student

Prostate Cancer Therapeutics Research Group

A/Prof. Arun Azad MBBS FRACP PhD
Group Leader

Dr. Sarah To PhD BSc (Hons)
NHMRC CJ MArtin Post Doctoral Fellow

Ms Patrica Bukczynska BSc
Senior Research Assistant

Ms. Maria Docanto BSc (Hons)
Senior Research Assistant

Ms. Heidi Fettke BSc (Hons)
PhD Student

Dr. Edmond Kwan MBBS FRACP
PhD Student

Dr. Mark Waltham PhD BSc (Hons)
Research Scientist

Ms. Nicole Ng
Project Officer

Blood Cancer Therapeutics Research Group

A/Prof. Jake Shortt BMedSc MBChB FRACP FRCPA PhD
Group Leader

Dr Gareth Gregory MBBS (Hons) PhD FRACP FRCPA
Haematologist

Dr. Mark Waltham PhD BSc (Hons)
Research Scientist

Dr. Zahra Sabouri-Thompson MD PhD
Post Doctoral Fellow

Ms Belinda Maher BSc (Hons)
Research Assistant

Department Publications

2018

Singh S, Chan DL, Lui N, Fischer HD, Austin PC, Moody L, Segelov ERecurrence in resected gastroenteropancreatic tumours: A population-based study. JAMA Oncology. Doi: 10.1001/jamaoncol.2018.0024. Senior author

Tang M, Price JT, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis (2018). Expert Review of Anticancer Therapy. Volume 18(4), 339-349.

Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC, Segelov E. Recurrence in Resectable Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4(4): 583-585. Doi: 10.1001/jamancol.2018.0024

Sarah Q. To, Edmond M. Kwan, Heidi C. Fettke, Andrew Mant, Maria M. Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenho¨fer, Arun A. Azad. Expression of Androgen Receptor Splice Variant 7 or 9 in WholeBlood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer Eur Urol 2018. doi: 10.1016/j.eururo.2018.01.007. [Epub ahead of print]

2017  

Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, Segelov E.  Uncommon Anal Neoplasms. Surgical oncology clinics of North America. anal cancer edition Surgical Oncology Clinics of North America 26 2017 Jan 31;26(1):143-61.invited chapter editor and Senior author, Impact factor 2

Annala M, Nappi L, Azad A , Mo F, Fazli L, Chi KN, Wyatt AW.  Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical genitourinary cancer. 2017 Feb 1;15(1):e145-50.

Wein L, Rowe C, Brady B, Handolias D, Lipton L, Pook D , Stanley R, Haines I. Prevalence of systemic anticancer therapy for patients within the last 30 days of life: experience in a private hospital oncology group. Internal medicine journal. 2017 Mar 1;47(3):280-3.

Srivastava R .  The Interpreter. N Engl J Med. 2017 Mar 2;376:812-3

Sandler CX, Goldstein D, Horsfield S, Bennett BK, Friedlander M, Bastick PA, Lewis CR, Segelov E , Boyle FM, Chin MT, Webber K.
Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue. Journal of pain and symptom management. 2017 May 11.

Chan DL, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. The Cochrane database of systematic reviews. 2017 Jun 27;6:CD007047.

Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. 2017 Jul 1;46(6):707-14.

Chan D, Segelov E, Ferone D, Albertelli M, Pavlakis N,  Singh S.  Escalated dose somatostatin analogues for anti-proliferative effect in GEP-NETS: A systematic review. Endocrine 2017 Jul 19:1-0. contributing author, Impact factor 3.1

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JFG, Anson-Cartwright L, Chung PWM, Warde PR, Moore MJ, Bedar PL, Tran B. (in press).  Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumours. Clin Genitourin Cancer. doi: 10.1016/j.clgc.2017.08.012

Segelov E, Lordick F, Goldstein D, ChantrillL, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price T.  Current challenges in optimizing systemic therapy for patients with pancreatic cancer: Expert perspectives from the Australian Gastrointestinal Trials Group with invited international faculty. Expert Review in Anticancer Therapy. Published online Sept 5 2017 doi.org/10.1080/14737140.2017.1369882. First author, Impact factor 2

Chan DLH, Segelov E, Wong RSH, Smith A, Herbertson RA, Li B, Tebbutt N, Price T, Pavlakis N.  Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2017 Issue 6, Art: CD007047.Contributing author, impact factor 6.1

Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, Kwan EM, Fox S, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal M, Desai J. (in press). Precision medicine using a clinician-directed, tailored approach to molecular profiling. Asia Pac J Clin Oncol. doi: 10.1111/ajco.12787

Chan D, Segelov E, Singh S.Update on the use of everolimus in the management of metastatic neuroendocrine tumors of gastrointestinal origin. Invited article; Therapeutic advances in gastroenterology; 2017: 10 (1) 132-141. One of three contributing authors, Impact factor 5 doi:10.1177/1756283X16674660

Templeton, D. J. , Roberts, J. M. , Poynten, I. M. , Law, C , Hillman, R. J. , Farnsworth, A., Fairley, C. K.  , Tabrizi, S. N. , Grulich, A. E. , Jin, F. , Acraman, B. , Carr, A. , Carroll, S. , Cooper, D. , Cornall, A.  , Crampton, L. , Fairley, K. , Feeney, L. , Fraissard, E. , Howard, K. & 21 others Law, M., Machalek, D. A., McCaffery, K., McGrath, P., Mellor, R., Norris, R. , O'Dwyer, M., Pendlebury, S., Petoumenos, K., Phillips, S., Poynten, I. M., Prestage, G., Richards, A., Schema, L., Seeds, D., Segelov E , Templeton, D., Thurloe, J. K., Tong, W. W. Y., Varma, R.
On behalf of the SPANC Study Team Prevalence and predictors of unsatisfactory anal cytology tests in a cohort of gay and bisexual men in Sydney, Australia: Baseline findings from the Study of the Prevention of Anal Cancer (SPANC). 2017 European Journal of Cancer Prevention. 26, 3, p. 212-216
 

For 2016 publications click here

Department Abstracts

2018

Segelov E, Williams D, Chia J, Sieber O. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. Presented at ASCO GI 2018.

Clarke S, Burge M,  Feeney K, Jones K, Gibbs P, Molloy M,Marx G, Price T, Reece W, Segelov E, Tebbutt N.  Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab. Presented at ASCO GI 2018.

Blinman P, Goldstein D, Martin A, Jefford M, Boadle D, Tebbutt N, Paul J, Haydon A, Segelov E, Stockler M. Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? American Society of Clinical Oncology Annual Meeting 2018(accepted)

2017

Poon P, Shaw T, Franco M, Runacres F, William L, Yoong J. Successful large volume ‘lymphocentesis’ for refractory lymphoedema in lower and upper limbs. Internal Medicine Journal. 2017 May 1;47(5):607-.

Lee B, Cohen J, Lipton L, Tie J, Javed A, Li , Goldstein D, Cooray P, B Nagrial A, Burge M, Tebbutt N, Nikfarjam M, Harris M, O’Broin-Lennon, Wolfganag C, TomasettiC, Papadopoulos NJ, Kinzler K, Vogelstein B, Gibbs P. Potential role of circulating tumour DNA( ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer. ASCO GI 2017 Abs 4101

Cubillo A, dean A, Munoz A, Pazo Cid R, Martin M, Mercade T, Lipton L, Harris M, Santasusana J, Gullen C, Tebbutt N, Cooray P, Sohal D, Zalupski M, Kolevska T, Stagg R , Holmgren E, Goldstein D. Yosemite : A 3 arm Double blind randomised Phase 2 study of Gemcitabine , Abraxane amd Placebo versus Gemcitabine , Abraxane and either 1 or 2 truncated courses of Demcizumab .620 PD ESMO 2017

Jong I, Croagh D, Harris M, Bradney M. Biodistribution of implanted phosphorus -32 into unresectable locally advanced pancreatic adenocarcinoma given in combination with gemcitabine +nab-paclitaxel chemotherapy – A single centre experience. World Federation of Nuclear Medicine and Biology Congress 2018 Abstract 1745. Accepted December 2017

 

 

 Updated June 2018

 

Refer A Patient 

Symptom and Urgent Review Clinic (SURC)


The SURC clinic in Dandenong will be in operation from Monday the 5th of February 2018. If you require a patient referral to the SURC pharmacist or nurse, please call the team via phone on 0435 960 916 or email 

Dandenong.SURC@monashhealth.org

McGarth Foundation Breast Cancer Nurse

Dandenong Hospital has welcomed its first McGrath Foundation Breast Care Nurse in Feburary 2018 and is offering free support to patients and their families - complete care programs including support groups & emotional resilience worskops are available.

Please contact Katie Evans via phone on 0466 014 350 or email her at katie.evans@monashhealth.org

Conference Participation

ESMO Asia 2017

 

Optimal Care Pathways
for Cancer Patients

The optimal cancer care pathways (OPS) describe the optimal cancer care for specific tumour types. They map the patient journey, aiming to foster an understanding of the whole pathway and its components to promote quality cancer and patient experiences.

Cancer: What to Expect?

Information for patients  

Information for Clinicians

McGrath Foundation Breast Cancer Nurse

Cancer Prevention

Between 30-50% of all cases are preventable. Prevention offers the most cost-effective long-term strategy for the control of cancer. National policies programmes should be implemented to raise awareness, to reduce exposure to cancer risk factors and to ensure that people are provided with the information and support they need to adopt healthy lifestyles.

Cancer Prevention Link